Who are we?
Tzamal has been at the forefront of medical technology representing some of the most distinguished medical device companies in the world, for more than 35 years. During its first 25 years, the company represented established companies and focused on direct sales. Companies which chose Tzamal to represent them include Johnson & Johnson, Ohmeda (B&D) and Schneider (Pfizer).
Medical Innovation Specialists
Just over a decade ago Tzamal embarked on a bold and new path and therefore underwent a major reorganization. The company decided to devote almost a third of its resources to representing up and coming med-techs offering unique, innovative solutions. An intensive marketing program was introduced, specifically designed to familiarize the medical community with medical innovations. Thanks to this strategy, Tzamal is today recognized for its expertise in promoting and achieving sales for young medical technology innovators. The company is proud of its unique ability to break-down barriers and guide hospital administrators throughout replacement of obsolete medical technologies with innovative ones.
Putting Patients First
Stunning results have shown the new company succeeded in surpassing the sales peak of its predecessor within half the time. Today Tzamal enjoys annual sales of over $27 million and growing. The secret of our success lies in great part in our continuous pursue for better patient care as a main goal..Our commitment to state-of-the art health care is what drives our outstanding results.
Comprehensive Solution
Tzamal is active in most major med-tech markets via its six subsidiaries:
Tzamal Jakobsohn – Innovative devices and technology for surgery, orthopedics, cardiology, neurosurgery and spinal applications.
Tzamal Bio-Pharma – Specialty biotechnologies and pharmaceuticals, orphan drugs for rare diseases
Tzamal M.P.VET – Veterinary products, technologies and equipment
Tzamal 2B Capital Medical Equipment – High-tech capital equipment for all areas of healthcare industry
Tzamal Medicare – Innovative technology for primary and home care
Tzamal D-Chem Laboratories – Chemicals for research
Actively Advancing Innovation
Besides marketing existing products\companies, Tzamal is also greatly involved in development of innovative new medical technologies by mentoring and financing promising medical technology start-ups in a wide variety of fields. Via its subsidiary Tzamal Investments the company is closely guiding and financing some two dozen young companies.
Drugs Disributed by Tzamal Bio-Pharma Ltd
Thiazolidinediones. Pioglitazone 15, 30, 45 mg. TABS.: 15 mg, 30 mg, 45
mg x 28.
Once dly with or w/o food. Initial treat.:
15 mg or 30 mg once dly; may be
increased up to 45 mg once dly. May
be used in combination with insulin.
See lit. Elderly: No dose adjustment is
necessary. Renal impair.ent: No dose
adjustment is necessary in pts. with
impaired renal func. (CLcr > 4 ml/min) Not to be used in dialysed pts. Hepatic
impair.ent: should not be used in pts.
With hepatic impair.ent Paediatric: Not
to be used in children and adolescents
under 18 yrs of age.
As second or third line treatment of type 2
diabetes mellitus: as monotherapy: in
adult patients (particularly overweight
patients) inadequately controlled by diet
and exercise for whom metformin is
inappropriate because of
contraindications or intolerance as dual
oral therapy in combination with
metformin, in adult patients (particularly
overweight patients) with insufficient
glycaemic control despite maximal
tolerated dose of monotherapy with
metformin; with a sulphonylurea, only in
adult patients who show intolerance to
metformin or for whom metformin is
contraindicated, with insufficient
glycaemic control despite maximal
tolerated dose of monotherapy with a
sulphonylurea. As triple oral therapy in
combination with: metformin and a
sulphonylurea, in adult patients
(particularly overweight patients) with
insufficient glycaemic control despite dual
oral therapy.Pioglitazone is also indicated
for combination with insulin in type 2
diabetes mellitus adult patients with
insufficient glycaemic control on insulin
for whom metformin is inappropriate
because of contraindications or
intolerance.After initiation of therapy with
pioglitazone, patients should be reviewed
after 3 to 6 months to assess adequacy of
response to treatment (e.g. reduction in
HbA1c). In patients who fail to show an
adequate response, pioglitazone should
be discontinued. In light of potential risks
with prolonged therapy, prescribers should
confirm at subsequent routine reviews
that the benefit of pioglitazone is
maintained.
C/I: Hypersens. to product; cardiac
failure or history of cardiac failure (NYHA
stages I to IV); hepatic impair.ent;
diabetic ketoacidosis; current bladder
cancer or a history of bladder cancer;
uninvestigated macroscopic haematuria.
Antiplatelet Agent. Tirofiban HCl Monohydrate 0.05 mg/ml. VIAL FOR INJECT: 1 x 12.5 mg/50 ml
(0.25 mg/ml).
INFUS. BAG: 1 x 12.5 mg/250 ml (0.05
mg/ml). Initial: 0.4 μg/kg/min of
diluted sol. by I.V. Then 0.1 μg/kg/min.
See lit.
In comb. with heparin in unstable
ang. or non-Q-wave M.I., prevent card.
ischem. events, acute coronary syndr.
(incl. medically managed and
undergoing PTCA or atherectomy). See
lit.
TCA. Clomipramine HCl 25 mg, 75 mg. TABS: 30 x 25 mg. 1 tab. dly. in div.
doses. Severe cases: 75-100 mg dly. in
div. doses.
Depress. varying origin. Child and adolesc.
(0-17 yrs): Not recommend. Obsess.
compuls. disords: Not for child under 5 yrs.
C/I: Not to be used with or within 14
days of tmt. with MAO inhibit., liver
damage, card. or circulat. failure,
hypotens. tendency, glaucoma, urine
retent.
Angiotensin II Antagonist. Candesartan Cilexetil 4 mg, 8 mg, 16 mg. TABS: 28 x 8 mg, 16 mg. Initial: 8 or 16
mg 1 x dly. Maint: 8 or 16 mg 1 x dly,
with or without food. Max. effect: 4
wks.
Hypertens.
C/I: Hypersens., pregn., lact.
Angiotensin II Antagonist, Diuretics. Candesartan Cilexetil 16 mg, Hydrochlorothiazide 12.5 mg. TABS: 28. 1 tab x dly with or without
food. Elderly: No special dosage. Use
in pts with impair. ren. fusal: see lit.
Not recommend. for child.
Antihypertens. effect usually attained
within 4 wks.
Essent. hypertens. where monother. with
candesartan cilexetil or HCTZ is not
suffic.
C/I: Hypersens., severe ren. impair.,
severe hepat. impair and / or cholestas.,
gout.
Nitrogen mustard analogues. Bendamustine Hydrochloride 25,100 mg. VIAL(Pwdr. for concentrate for sol. for IV infus.):1×25,100 mg.
Monother. for CLL 100 mg/m² bdy. surface area bendamustine HCl on days 1 and 2; every 4 wks. up to 6 times.
Monother. for indolent non-Hodgkin’s lymphomas refract. to rituximab
120 mg/m² bdy. surface area bendamustine HCl on days 1 and 2;
every 3 wks. for at least 6 times.
Follicular non-Hodgkin’s lymphoma: Comb. with rituximab
The dose is 90 mg/m² body surface area bendamustine HCl on days 1 and 2
plus 375 mg/m² rituximab on day 1; repetition every 4 wks. See lit.
1st -line of CLL (Binet stage B or C) in pts. for whom fludarabine comb. chemother. is not appropiate. Indolent non-Hodgkin’s lymphomas as monother.in pts., who have progress. during or within 6 mnths. follow. tmt. with rituximab or a rituximab contain. regimen. Follicular non-Hodgkin’s lymphoma as 1st line tmt. in comb. with rituximab.
C/I: Hypersens.
Lact.
Sev. hep. impair. (serum bilirub. > 3.0 mg/dl).
Jaundice.
Severe bone marrow suppres. and severe blood count alterations (leukocyte and/or platelet values dropped to < 3,000/μl or < 75,000/μl, respectively).
